Brind.
  1. Apogee Therapeutics' drug APG777 met primary endpoints in clinical trials for the treatment of atopic dermatitis.

Apogee Therapeutics conducted the Phase 2 APEX clinical trial for its anti-IL-13 antibody, APG777.

1 report, 0 independent Updated Jul 7
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Apogee Therapeutics conducted the Phase 2 APEX clinical trial for its anti-IL-13 antibody, APG777.

Who's involved

What this event is mainly about
Michael HendersonApex

Keep exploring

Part of

Apogee Therapeutics' drug APG777 met primary endpoints in clinical trials for the treatment of atopic dermatitis. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet